Skip to main content
Log in

Diuretika und extrakorporale Verfahren zur Behandlung des kardiorenalen Syndroms

Diuretics and extracorporeal procedures for treatment of cardiorenal syndrome

  • Leitthema
  • Published:
Der Nephrologe Aims and scope

Zusammenfassung

Eine akute oder chronische Herzinsuffizienz kann zu einer Verminderung der Nierenfunktion im Sinne eines kardiorenalen Syndroms (CRS) führen. Ein wesentliches klinisches Problem dieser Patienten ist eine Hypervolämie, zusammen mit sich verschlechternder Nierenfunktion. Die Behandlung besteht dabei zunächst in der Gabe von Diuretika. Allerdings stößt diese v. a. durch die Entwicklung einer Diuretikaresistenz häufig an ihre Grenzen. Ziel dieser Übersicht ist es, die Wirksamkeit der über die konservative medikamentöse Therapie hinausgehenden extrakorporalen Behandlungsmöglichkeiten im Sinne der Peritonealdialyse (PD), der Hämodialyse (HD) oder einer alleinigen maschinellen Ultrafiltration darzustellen. Die Bauchfelldialyse kann bei Patienten mit manifestem CRS die Lebensqualität und die Herzfunktion verbessern sowie die Zahl der Krankenhausaufenthalte vermindern. Auch die HD kann zur Behandlung eingesetzt werden. Allerdings sind damit ungünstige Effekte wie Hypotonien und der Verlust der Diurese verbunden. Eine alleinige maschinelle Ultrafiltration scheint im Gegensatz zu einer Diuretikabehandlung keine wesentlichen Vorteile zu haben.

Abstract

Acute or chronic heart failure can lead to a reduction in kidney function presenting as cardiorenal syndrome (CRS). A substantial clinical problem in such patients is hypervolemia in combination with deteriorating renal function. The treatment initially consists of diuretics at this clinical stage; however, development of resistance against diuretics often limits successful therapy. The aim of this overview is to provide an overview of extracorporeal treatment options, such as peritoneal dialysis (PD), hemodialysis (HD), and mechanical ultrafiltration alone. In patients with manifest CRS the use of PD can result in improvement in the quality of life and improve cardiac function as well as reduction in the number of hospital stays. The HD is also an option in the treatment of such patients; however, it is often related to unfavorable effects, such as hypotension and a reduction in diuresis. Mechanical ultrafiltration alone does not seem to provide any advantages as compared to diuretic treatment in patients with CRS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Literatur

  1. Barrios HS, Palmer A, Khan T et al (2014) Successful long-term intermittent hemodialysis in a patient with left ventricular assist device. Clin Nephrol 82:407–410

    Article  Google Scholar 

  2. Bart BA, Boyle A, Bank AJ et al (2005) Ultrafiltration versus usual care for hospitalized patients with heart failure: the Relief for Acutely Fluid-Overloaded Patients With Decompensated Congestive Heart Failure (RAPID-CHF) trial. J Am Coll Cardiol 46:2043–2046

    Article  Google Scholar 

  3. Bart BA, Goldsmith SR, Lee KL et al (2012) Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 367:2296–2304

    Article  CAS  Google Scholar 

  4. Bertoli SV, Musetti C, Ciurlino D et al (2014) Peritoneal ultrafiltration in refractory heart failure: a cohort study. Perit Dial Int 34:64–70

    Article  CAS  Google Scholar 

  5. Cnossen TT, Kooman JP, Konings CJ et al (2010) Peritoneal dialysis in patients with primary cardiac failure complicated by renal failure. Blood Purif 30:146–152

    Article  CAS  Google Scholar 

  6. Cnossen TT, Kooman JP, Krepel HP et al (2012) Prospective study on clinical effects of renal replacement therapy in treatment-resistant congestive heart failure. Nephrol Dial Transplant 27:2794–2799

    Article  Google Scholar 

  7. Costanzo MR, Guglin ME, Saltzberg MT et al (2007) Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 49:675–683

    Article  CAS  Google Scholar 

  8. Courivaud C, Kazory A, Crepin T et al (2014) Peritoneal dialysis reduces the number of hospitalization days in heart failure patients refractory to diuretics. Perit Dial Int 34:100–108

    Article  CAS  Google Scholar 

  9. Damman K, Testani JM (2015) The kidney in heart failure: an update. Eur Heart J 36:1437–1444

    Article  Google Scholar 

  10. Guglielmi AA, Guglielmi KE, Bhat G et al (2014) Peritoneal dialysis after left ventricular assist device placement. ASAIO J 60:127–128

    Article  CAS  Google Scholar 

  11. Koch M, Haastert B, Kohnle M et al (2012) Peritoneal dialysis relieves clinical symptoms and is well tolerated in patients with refractory heart failure and chronic kidney disease. Eur J Heart Fail 14:530–539

    Article  Google Scholar 

  12. Kunin M, Arad M, Dinour D et al (2013) Peritoneal dialysis in patients with refractory congestive heart failure: potential prognostic factors. Blood Purif 35:285–294

    Article  CAS  Google Scholar 

  13. Leskovar B, Furlan T, Poznic S et al (2017) Hemodialysis treatment of cardiorenal syndrome. Clin Nephrol 88:57–60

    Article  Google Scholar 

  14. Nunez J, Gonzalez M, Minana G et al (2012) Continuous ambulatory peritoneal dialysis as a therapeutic alternative in patients with advanced congestive heart failure. Eur J Heart Fail 14:540–548

    Article  CAS  Google Scholar 

  15. O’connor CM, Abraham WT, Albert NM et al (2008) Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J 156:662–673

    Article  Google Scholar 

  16. Obi Y, Kim T, Kovesdy CP et al (2016) Current and potential therapeutic strategies for Hemodynamic Cardiorenal syndrome. Cardiorenal Med 6:83–98

    Article  CAS  Google Scholar 

  17. Quader MA, Kumar D, Shah KB et al (2014) Safety analysis of intermittent hemodialysis in patients with continuous flow left ventricular assist devices. Hemodial Int 18:205–209

    Article  Google Scholar 

  18. Rao VS, Planavsky N, Hanberg JS et al (2017) Compensatory distal reabsorption drives diuretic resistance in human heart failure. J Am Soc Nephrol 28:3414–3424

    Article  Google Scholar 

  19. Rizkallah J, Sood MM, Reslerova M et al (2013) Reduced hospitalizations in severe, refractory congestive heart failure with peritoneal dialysis: a consecutive case series. Clin Nephrol 80:334–341

    Article  Google Scholar 

  20. Ronco C, Di Lullo L (2017) Cardiorenal syndrome in Western countries: epidemiology, diagnosis and management approaches. Kidney Dis (basel) 2:151–163

    Article  Google Scholar 

  21. Sanchez JE, Ortega T, Rodriguez C et al (2010) Efficacy of peritoneal ultrafiltration in the treatment of refractory congestive heart failure. Nephrol Dial Transplant 25:605–610

    Article  Google Scholar 

  22. Shao Q, Xia Y, Zhao M et al (2018) Effectiveness and safety of peritoneal dialysis treatment in patients with refractory congestive heart failure due to chronic cardiorenal syndrome. Biomed Res Int 2018:6529283

    PubMed  PubMed Central  Google Scholar 

  23. Thomas BA, Logar CM, Anderson AE (2012) Renal replacement therapy in congestive heart failure requiring left ventricular assist device augmentation. Perit Dial Int 32:386–392

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to J. Lutz.

Ethics declarations

Interessenkonflikt

J. Lutz, A. Rieke und W. Bojara geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Additional information

Redaktion

U. Heemann, München

J. Lutz, Koblenz

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lutz, J., Rieke, A. & Bojara, W. Diuretika und extrakorporale Verfahren zur Behandlung des kardiorenalen Syndroms. Nephrologe 13, 389–394 (2018). https://doi.org/10.1007/s11560-018-0282-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11560-018-0282-y

Schlüsselwörter

Keywords

Navigation